PAPERS

Prasad A, Husain S, Quyyumi AA. Contribution of Bradykinin receptor dysfunction to abnormal coronary vasomotion in humans. Journal of the American College of Cardiology: 2000; 36:1467-73, November 1, 2000

Prasad A, Husain S, Quyyumi AA. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin converting enzyme inhibition: a potential role in bradykinin. Journal of American College of Cardiology. 33(3): 796-804, March 1, 1999

Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA.. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 97(8): 716-20, Mar 3, 1998

Quyyumi AA, Dakak N, Mulcahy D, Andrews NP, Husain, S, Panza JA, Cannon RO 3rd. Nitric Oxide activity in the atherosclerosis human coronary circulation. Journal of the American College of Cardiology. 29(2): 308-17, Feb 1997

Mulcahy D, Husain S, Zalos G, Rehmann A, Andrews NP, Schenke WH, Quyyumi AA. Ischemia during ambulatory monitoring as a prognosticator in patients with stable coronary artery disease. JAMA. 277 (4): 318-24, Jan 22-29, 1997

Quyyumi AA, Mulcahy D, Andrews NP, Husain S. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance. Circulation. 95(I): 104-10, Jan 7, 1997

Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO. Nitric oxide activity in human coronary circulation: Impact of risk factors for coronary atherosclerosis. J Clin Invest; Vol 95, 1747-11755. April 1995

Diodati JG, Cannon RO 3rd, Husain S, Quyyumi AA. Inhibitory effect of nitroglycerine and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Journal of the American Journal of Cardiology. 75(7): 443-8, Mar 1, 1995
Dakak N, Husain S, Mulcahy DM, Andrews NP, Panza JA, Waclawiw M, Schenke W, Quyyumi AA. Contribution of nitric oxide to reactive hyperemia: Impact of endothelial dysfunction and effect of L-arginine. Hypertension (in press)

Prasad A, Husain S, Quyyumi AA. Angiotensin converting enzyme inhibition improves human coronary endothelial dysfunction by increasing nitric oxide bioavailability. (Submitted to Circulation).

Prasad A, Narayanan S, Husain S, et alAngiotensin-converting enzyme inhibition improves human coronary endothelial dysfunction by increasing nitric oxide bioavailability. An effect modulated by the insertion-deletion polymorphism. Circulation (in press).

Prasad A, Husain S, Quyyumi AA. Human peripheral endothelial dysfunction and nitric oxide bioavailablity improves with angiotensin converting enzyme inhibition. (Submitted to Circulation).

Husain S and Dakak N, Mulcahy D, Andrews NP, Panzer J, Quyyumi AA. Contribution of Nitric Oxide to reactive hyperemia: Impact of endothelial dysfunction and effect of L-arginine. (Submitted to Circulation).